The Adverse Double-Hit Effect of Combining Cytogenetic Abnormalities and ISS Stage III on the Outcome of Patients with Newly-Diagnosed Multiple Myeloma

Fengyan Jin,Shaji Kumar,Yun Dai

DOI: https://doi.org/10.1016/j.clml.2019.09.107

IF: 2.822

2019-01-01

Clinical Lymphoma Myeloma & Leukemia

Abstract:Emerging evidence suggests poor outcome of multiple myeloma (MM) patients carrying multiple adverse factors including high risk cytogenetic abnormalities (HRCA) and ISS stage III, thereby termed double-hit MM (DHMM). However, it remains uncertain how to define DHMM and its clinical significance due to lack of confirming study. To this end, our study aims to examine the prognostic values of co-occurrences of multiple HRCAs or their combination with ISS stage III in patients with newly-diagnosed MM (NDMM). A total of 307 NDMM patients who had baseline information of CAs detected by FISH and ISS staging, as well as received at least 4 cycles of treatment were included in this study. According to the consensus of the IMWG in 2016, 1q gain, del(17p), t[4;14], and t[14;16] were defined as HRCA, while del(13q14) was considered as a non-independent adverse CA. DHMM was defined as co-occurrences of either a) >= 2 HRCAs or b) at least 1 HRCA plus ISS stage III. In 180 cases harboring HRCAs, 23.3% and 10.5% patients carried only 1 HRCA or >= 2 HRCAs with a median PFS of 32.2 and 12.1 months (p = 0.0004), as well as a median OS of 65.6 and 29.3 months (p = 0.027), respectively. Interestingly, another subgroup of patients (17.2%) carrying 1 HRCA plus del(13q14) also displayed significantly shorter PFS (19.1 months, p = 0.046) and OS (29.6 months, p = 0.055), compared to those who had only 1 HRCA. In 140 cases harboring 1q gain, patients who carried >= 1 additional HRCAs had a median PFS of 11.2 months and a median OS of 18.9 months, significantly worse than those who had only 1q gain (PFS, 30.1 months, p = 0.0009; OS, 65.6 months, p = 0.0008). Patients carrying del(17p) with >= 1 additional HRCAs had a median PFS of 12.1 months and a median OS of 31.5 months. Moreover, patients carrying both 1q gain and del(17p) had significantly shorter PFS and OS than either 1q gain or del(17p) alone (PFS, p = 0.008 or p = 0.001; OS, p = 0.001 or p = 0.006), respectively. In 89 ISS III cases, patients with >= 1 HRCAs had a median PFS of 13.2 months and a median OS of 15.2 months, clearly worse than those without HRCA (PFS, 21.0 months, p = 0.032; OS, 43.8 months, p = 0.057). Last, ISS III patients carrying both 1q gain and del(17p) had the worst outcome with a median PFS of 2.3 months and a median OS of 4.5 months, compared to those with only one of these two HRCAs (PFS, 15.8 months; OS, 24.5 months). In conclusion, our findings argue that patients either carrying two or more HRCA or at ISS III stage with at least one HRCA, so called DHMM, have significantly worse outcome (both PFS and OS), than those carrying only one HRCA or at ISS III stage, respectively. They also suggest that integration of the DHMM features into the current risk stratification criteria is helpful for more precisely identifying patients with high-risk or even worse disease at diagnosis, whose outcomes remain grim even in the era of novel therapies.